uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The company develops AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia; and AMT-126, a gene therapy for the treatment of congestive heart failure and AMT-130 to treat huntington's disease. The company has collaboration and license agreements with Bristol-Myers Squibb Company, 4D Molecular Therapeutics, Synpromics. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:QURE
CUSIPN/A
Phone31-20-566-7394
Debt
Debt-to-Equity Ratio0.16
Current Ratio5.48
Quick Ratio5.48
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$13.11 million
Price / Sales102.30
Cash FlowN/A
Price / CashN/A
Book Value$2.90 per share
Price / Book12.48
Profitability
EPS (Most Recent Fiscal Year)($2.94)
Net Income$-79,260,000.00
Net Margins-586.38%
Return on Equity-131.55%
Return on Assets-44.52%
Miscellaneous
Employees202
Outstanding Shares37,070,000
Uniqure (NASDAQ:QURE) Frequently Asked Questions
What is Uniqure's stock symbol?
Uniqure trades on the NASDAQ under the ticker symbol "QURE."
How were Uniqure's earnings last quarter?
Uniqure NV (NASDAQ:QURE) announced its quarterly earnings results on Monday, April, 30th. The biotechnology company reported ($0.59) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.74) by $0.15. The biotechnology company had revenue of $3.48 million for the quarter, compared to analyst estimates of $3.08 million. Uniqure had a negative net margin of 586.38% and a negative return on equity of 131.55%. View Uniqure's Earnings History.
When is Uniqure's next earnings date?
What price target have analysts set for QURE?
8 brokers have issued 12 month price objectives for Uniqure's shares. Their forecasts range from $13.00 to $63.00. On average, they expect Uniqure's stock price to reach $35.25 in the next twelve months. View Analyst Ratings for Uniqure.
Are investors shorting Uniqure?
Uniqure saw a increase in short interest in the month of May. As of May 31st, there was short interest totalling 1,255,022 shares, an increase of 59.8% from the May 15th total of 785,536 shares. Based on an average daily volume of 399,567 shares, the days-to-cover ratio is currently 3.1 days. Approximately 6.3% of the shares of the stock are sold short. View Uniqure's Current Options Chain.
Who are some of Uniqure's key competitors?
Some companies that are related to Uniqure include Dr.Reddy's Laboratories (RDY), Agios Pharmaceuticals (AGIO), Catalent (CTLT), Loxo Oncology (LOXO), FibroGen (FGEN), Ionis Pharmaceuticals (IONS), United Therapeutics (UTHR), GALAPAGOS NV/S (GLPG), Taro Pharmaceutical Industries (TARO), Ligand Pharmaceuticals (LGND), GW Pharmaceuticals (GWPH), Array Biopharma (ARRY), Ultragenyx Pharmaceutical (RARE), Madrigal Pharmaceuticals (MDGL) and HUTCHISON CHINA/S (HCM).
Who are Uniqure's key executives?
Uniqure's management team includes the folowing people:
- Mr. Matthew Craig Kapusta, CEO, Interim CFO & Exec. Director (Age 46)
- Dr. Sander Van Deventer, Co-Founder, Chief Scientific Officer, Director, Advisor & GM of Amsterdam (Age 64)
- Prof. Hugo Katus, Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany
- Dr. Scott T. McMillan Ph.D., Chief Operating Officer (Age 59)
- Mr. Christian Klemt, Chief Accounting Officer (Age 45)
Has Uniqure been receiving favorable news coverage?
News articles about QURE stock have trended somewhat positive recently, according to Accern. The research firm identifies negative and positive press coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Uniqure earned a coverage optimism score of 0.08 on Accern's scale. They also assigned media coverage about the biotechnology company an impact score of 44.63 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near future.
Who are Uniqure's major shareholders?
Uniqure's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include FORUNIQURE B.V. (13.81%), COLLER INTERNATIONAL PARTNERS V A LP (5.73%), Federated Investors Inc. PA (2.89%), Millennium Management LLC (2.06%), Foresite Capital Management IV LLC (1.52%) and BlackRock Inc. (1.37%). Company insiders that own Uniqure stock include Christian Klemt, David Schaffer, Deventer Sander Van, Harald Petry, Maria E Cantor, Matthew C Kapusta and Steven Zelenkofske. View Institutional Ownership Trends for Uniqure.
Which institutional investors are selling Uniqure stock?
QURE stock was sold by a variety of institutional investors in the last quarter, including Prosight Management LP, Foresite Capital Management IV LLC, BlackRock Inc. and Barclays PLC. Company insiders that have sold Uniqure company stock in the last year include Christian Klemt, David Schaffer, Deventer Sander Van, Harald Petry, Maria E Cantor, Matthew C Kapusta and Steven Zelenkofske. View Insider Buying and Selling for Uniqure.
Which institutional investors are buying Uniqure stock?
QURE stock was acquired by a variety of institutional investors in the last quarter, including Federated Investors Inc. PA, Millennium Management LLC, Eventide Asset Management LLC, Sphera Funds Management LTD., venBio Select Advisor LLC, Spark Investment Management LLC, California Public Employees Retirement System and DekaBank Deutsche Girozentrale. View Insider Buying and Selling for Uniqure.
How do I buy shares of Uniqure?
Shares of QURE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Uniqure's stock price today?
One share of QURE stock can currently be purchased for approximately $36.18.
How big of a company is Uniqure?
Uniqure has a market capitalization of $1.46 billion and generates $13.11 million in revenue each year. The biotechnology company earns $-79,260,000.00 in net income (profit) each year or ($2.94) on an earnings per share basis. Uniqure employs 202 workers across the globe.
How can I contact Uniqure?
Uniqure's mailing address is PAASHEUVELWEG 25A, AMSTERDAM P7, 1105 BP. The biotechnology company can be reached via phone at 31-20-566-7394 or via email at [email protected]
MarketBeat Community Rating for Uniqure (QURE)
MarketBeat's community ratings are surveys of what our community members think about Uniqure and other stocks. Vote "Outperform" if you believe QURE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe QURE will underperform the S&P 500 over the long term. You may vote once every thirty days.
